

1 A bill to be entitled
 2 An act relating to xylazine; amending s. 893.03, F.S.;
 3 providing for use of xylazine as an animal drug in
 4 certain circumstances; providing an effective date.

5
 6 Be It Enacted by the Legislature of the State of Florida:

7
 8 Section 1. Paragraph (c) of subsection (1) of section
 9 893.03, Florida Statutes, is amended to read:

10 893.03 Standards and schedules.—The substances enumerated
 11 in this section are controlled by this chapter. The controlled
 12 substances listed or to be listed in Schedules I, II, III, IV,
 13 and V are included by whatever official, common, usual,
 14 chemical, trade name, or class designated. The provisions of
 15 this section shall not be construed to include within any of the
 16 schedules contained in this section any excluded drugs listed
 17 within the purview of 21 C.F.R. s. 1308.22, styled "Excluded
 18 Substances"; 21 C.F.R. s. 1308.24, styled "Exempt Chemical
 19 Preparations"; 21 C.F.R. s. 1308.32, styled "Exempted
 20 Prescription Products"; or 21 C.F.R. s. 1308.34, styled "Exempt
 21 Anabolic Steroid Products."

22 (1) SCHEDULE I.—A substance in Schedule I has a high
 23 potential for abuse and has no currently accepted medical use in
 24 treatment in the United States and in its use under medical
 25 supervision does not meet accepted safety standards. The

26 following substances are controlled in Schedule I:

27 (c) Unless specifically excepted or unless listed in
28 another schedule, any material, compound, mixture, or
29 preparation that contains any quantity of the following
30 hallucinogenic substances or that contains any of their salts,
31 isomers, including optical, positional, or geometric isomers,
32 homologues, nitrogen-heterocyclic analogs, esters, ethers, and
33 salts of isomers, homologues, nitrogen-heterocyclic analogs,
34 esters, or ethers, if the existence of such salts, isomers, and
35 salts of isomers is possible within the specific chemical
36 designation or class description:

- 37 1. Alpha-Ethyltryptamine.
- 38 2. 4-Methylaminorex (2-Amino-4-methyl-5-phenyl-2-
39 oxazoline).
- 40 3. Aminorex (2-Amino-5-phenyl-2-oxazoline).
- 41 4. DOB (4-Bromo-2,5-dimethoxyamphetamine).
- 42 5. 2C-B (4-Bromo-2,5-dimethoxyphenethylamine).
- 43 6. Bufotenine.
- 44 7. Cannabis.
- 45 8. Cathinone.
- 46 9. DET (Diethyltryptamine).
- 47 10. 2,5-Dimethoxyamphetamine.
- 48 11. DOET (4-Ethyl-2,5-Dimethoxyamphetamine).
- 49 12. DMT (Dimethyltryptamine).
- 50 13. PCE (N-Ethyl-1-phenylcyclohexylamine) (Ethylamine

- 51 analog of phencyclidine).
- 52 14. JB-318 (N-Ethyl-3-piperidyl benzilate).
- 53 15. N-Ethylamphetamine.
- 54 16. Fenethylamine.
- 55 17. 3,4-Methylenedioxy-N-hydroxyamphetamine.
- 56 18. Ibogaine.
- 57 19. LSD (Lysergic acid diethylamide).
- 58 20. Mescaline.
- 59 21. Methcathinone.
- 60 22. 5-Methoxy-3,4-methylenedioxyamphetamine.
- 61 23. PMA (4-Methoxyamphetamine).
- 62 24. PMMA (4-Methoxymethamphetamine).
- 63 25. DOM (4-Methyl-2,5-dimethoxyamphetamine).
- 64 26. MDEA (3,4-Methylenedioxy-N-ethylamphetamine).
- 65 27. MDA (3,4-Methylenedioxyamphetamine).
- 66 28. JB-336 (N-Methyl-3-piperidyl benzilate).
- 67 29. N,N-Dimethylamphetamine.
- 68 30. Parahexyl.
- 69 31. Peyote.
- 70 32. PCPY (N-(1-Phenylcyclohexyl)-pyrrolidine) (Pyrrolidine
- 71 analog of phencyclidine).
- 72 33. Psilocybin.
- 73 34. Psilocyn.
- 74 35. Salvia divinorum, except for any drug product approved
- 75 by the United States Food and Drug Administration which contains

76 Salvia divinorum or its isomers, esters, ethers, salts, and
 77 salts of isomers, esters, and ethers, if the existence of such
 78 isomers, esters, ethers, and salts is possible within the
 79 specific chemical designation.

80 36. Salvinorin A, except for any drug product approved by
 81 the United States Food and Drug Administration which contains
 82 Salvinorin A or its isomers, esters, ethers, salts, and salts of
 83 isomers, esters, and ethers, if the existence of such isomers,
 84 esters, ethers, and salts is possible within the specific
 85 chemical designation.

86 37. Xylazine, except for a xylazine animal drug approved
 87 by the federal Food and Drug Administration when the use of the
 88 drug conforms to the approved application or is permitted under
 89 21 U.S.C. s. 360b(a) (4). The manufacturing, importing,
 90 distribution, prescribing, or sale of xylazine for human use is
 91 not subject to this exclusion.

92 38. TCP (1-[1-(2-Thienyl)-cyclohexyl]-piperidine)
 93 (Thiophene analog of phencyclidine).

94 39. 3,4,5-Trimethoxyamphetamine.

95 40. Methydone (3,4-Methylenedioxyamphetaminone).

96 41. MDPV (3,4-Methylenedioxypropylvalerone).

97 42. Methyldioxyamphetamine.

98 43. Methoxyamphetamine.

99 44. Fluoromethamphetamine.

100 45. Methylethamphetamine.

HB 743

2024

- 101 46. CP 47,497 (2-(3-Hydroxycyclohexyl)-5-(2-methyloctan-2-
 102 yl)phenol) and its dimethyloctyl (C8) homologue.
- 103 47. HU-210 [(6aR,10aR)-9-(Hydroxymethyl)-6,6-dimethyl-3-
 104 (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-
 105 ol].
- 106 48. JWH-018 (1-Pentyl-3-(1-naphthoyl)indole).
- 107 49. JWH-073 (1-Butyl-3-(1-naphthoyl)indole).
- 108 50. JWH-200 (1-[2-(4-Morpholinyl)ethyl]-3-(1-
 109 naphthoyl)indole).
- 110 51. BZP (Benzylpiperazine).
- 111 52. Fluorophenylpiperazine.
- 112 53. Methylphenylpiperazine.
- 113 54. Chlorophenylpiperazine.
- 114 55. Methoxyphenylpiperazine.
- 115 56. DBZP (1,4-Dibenzylpiperazine).
- 116 57. TFMPP (Trifluoromethylphenylpiperazine).
- 117 58. MBDB (Methylbenzodioxolylbutanamine) or (3,4-
 118 Methylenedioxy-N-methylbutanamine).
- 119 59. 5-Hydroxy-AMT (5-Hydroxy-alpha-methyltryptamine).
- 120 60. 5-Hydroxy-N-methyltryptamine.
- 121 61. 5-MeO-MIPT (5-Methoxy-N-methyl-N-isopropyltryptamine).
- 122 62. 5-MeO-AMT (5-Methoxy-alpha-methyltryptamine).
- 123 63. Methyltryptamine.
- 124 64. 5-MeO-DMT (5-Methoxy-N,N-dimethyltryptamine).
- 125 65. 5-Me-DMT (5-Methyl-N,N-dimethyltryptamine).

- 126 | 66. Tyramine (4-Hydroxyphenethylamine).
- 127 | 67. 5-MeO-DiPT (5-Methoxy-N,N-Diisopropyltryptamine).
- 128 | 68. DiPT (N,N-Diisopropyltryptamine).
- 129 | 69. DPT (N,N-Dipropyltryptamine).
- 130 | 70. 4-Hydroxy-DiPT (4-Hydroxy-N,N-diisopropyltryptamine).
- 131 | 71. 5-MeO-DALT (5-Methoxy-N,N-Diallyltryptamine).
- 132 | 72. DOI (4-Iodo-2,5-dimethoxyamphetamine).
- 133 | 73. DOC (4-Chloro-2,5-dimethoxyamphetamine).
- 134 | 74. 2C-E (4-Ethyl-2,5-dimethoxyphenethylamine).
- 135 | 75. 2C-T-4 (4-Isopropylthio-2,5-dimethoxyphenethylamine).
- 136 | 76. 2C-C (4-Chloro-2,5-dimethoxyphenethylamine).
- 137 | 77. 2C-T (4-Methylthio-2,5-dimethoxyphenethylamine).
- 138 | 78. 2C-T-2 (4-Ethylthio-2,5-dimethoxyphenethylamine).
- 139 | 79. 2C-T-7 (4-(n)-Propylthio-2,5-dimethoxyphenethylamine).
- 140 | 80. 2C-I (4-Iodo-2,5-dimethoxyphenethylamine).
- 141 | 81. Butylone (3,4-Methylenedioxy-alpha-
- 142 | methylaminobutyrophenone).
- 143 | 82. Ethcathinone.
- 144 | 83. Ethylone (3,4-Methylenedioxy-N-ethylcathinone).
- 145 | 84. Naphyrone (Naphthylpyrovalerone).
- 146 | 85. Dimethylone (3,4-Methylenedioxy-N,N-
- 147 | dimethylcathinone).
- 148 | 86. 3,4-Methylenedioxy-N,N-diethylcathinone.
- 149 | 87. 3,4-Methylenedioxy-propiofenone.
- 150 | 88. 3,4-Methylenedioxy-alpha-bromopropiofenone.

- 151 | 89. 3,4-Methylenedioxy-propiofenone-2-oxime.
- 152 | 90. 3,4-Methylenedioxy-N-acetylcathinone.
- 153 | 91. 3,4-Methylenedioxy-N-acetylmethcathinone.
- 154 | 92. 3,4-Methylenedioxy-N-acetylethcathinone.
- 155 | 93. Bromomethcathinone.
- 156 | 94. Buphedrone (alpha-Methylamino-butyrophenone).
- 157 | 95. Eutylone (3,4-Methylenedioxy-alpha-
- 158 | ethylaminobutyrophenone).
- 159 | 96. Dimethylcathinone.
- 160 | 97. Dimethylmethcathinone.
- 161 | 98. Pentylone (3,4-Methylenedioxy-alpha-
- 162 | methylaminovalerophenone).
- 163 | 99. MDPPP (3,4-Methylenedioxy-alpha-
- 164 | pyrrolidinopropiofenone).
- 165 | 100. MDPBP (3,4-Methylenedioxy-alpha-
- 166 | pyrrolidinobutyrophenone).
- 167 | 101. MOPPP (Methoxy-alpha-pyrrolidinopropiofenone).
- 168 | 102. MPHP (Methyl-alpha-pyrrolidinohexanophenone).
- 169 | 103. BTCP (Benzothiophenylcyclohexylpiperidine) or BCP
- 170 | (Benocyclidine).
- 171 | 104. F-MABP (Fluoromethylaminobutyrophenone).
- 172 | 105. MeO-PBP (Methoxypyrrolidinobutyrophenone).
- 173 | 106. Et-PBP (Ethylpyrrolidinobutyrophenone).
- 174 | 107. 3-Me-4-MeO-MCAT (3-Methyl-4-Methoxymethcathinone).
- 175 | 108. Me-EABP (Methylethylaminobutyrophenone).

- 176 | 109. Etizolam.
- 177 | 110. PPP (Pyrrolidinopropiophenone).
- 178 | 111. PBP (Pyrrolidinobutyrophenone).
- 179 | 112. PVP (Pyrrolidinovalerophenone) or
- 180 | (Pyrrolidinopentiophenone).
- 181 | 113. MPPP (Methyl-alpha-pyrrolidinopropiophenone).
- 182 | 114. JWH-007 (1-Pentyl-2-methyl-3-(1-naphthoyl) indole).
- 183 | 115. JWH-015 (1-Propyl-2-methyl-3-(1-naphthoyl) indole).
- 184 | 116. JWH-019 (1-Hexyl-3-(1-naphthoyl) indole).
- 185 | 117. JWH-020 (1-Heptyl-3-(1-naphthoyl) indole).
- 186 | 118. JWH-072 (1-Propyl-3-(1-naphthoyl) indole).
- 187 | 119. JWH-081 (1-Pentyl-3-(4-methoxy-1-naphthoyl) indole).
- 188 | 120. JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl) indole).
- 189 | 121. JWH-133 ((6aR,10aR)-6,6,9-Trimethyl-3-(2-
- 190 | methylpentan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene).
- 191 | 122. JWH-175 (1-Pentyl-3-(1-naphthylmethyl) indole).
- 192 | 123. JWH-201 (1-Pentyl-3-(4-methoxyphenylacetyl) indole).
- 193 | 124. JWH-203 (1-Pentyl-3-(2-chlorophenylacetyl) indole).
- 194 | 125. JWH-210 (1-Pentyl-3-(4-ethyl-1-naphthoyl) indole).
- 195 | 126. JWH-250 (1-Pentyl-3-(2-methoxyphenylacetyl) indole).
- 196 | 127. JWH-251 (1-Pentyl-3-(2-methylphenylacetyl) indole).
- 197 | 128. JWH-302 (1-Pentyl-3-(3-methoxyphenylacetyl) indole).
- 198 | 129. JWH-398 (1-Pentyl-3-(4-chloro-1-naphthoyl) indole).
- 199 | 130. HU-211 ((6aS,10aS)-9-(Hydroxymethyl)-6,6-dimethyl-3-
- 200 | (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-

HB 743

2024

- 201 ol).
- 202 131. HU-308 ([(1R,2R,5R)-2-[2,6-Dimethoxy-4-(2-
- 203 methyloctan-2-yl)phenyl]-7,7-dimethyl-4-bicyclo[3.1.1]hept-3-
- 204 enyl] methanol).
- 205 132. HU-331 (3-Hydroxy-2-[(1R,6R)-3-methyl-6-(1-
- 206 methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-2,5-cyclohexadiene-
- 207 1,4-dione).
- 208 133. CB-13 (4-Pentyloxy-1-(1-naphthoyl)naphthalene).
- 209 134. CB-25 (N-Cyclopropyl-11-(3-hydroxy-5-pentylphenoxy)-
- 210 undecanamide).
- 211 135. CB-52 (N-Cyclopropyl-11-(2-hexyl-5-hydroxyphenoxy)-
- 212 undecanamide).
- 213 136. CP 55,940 (2-[3-Hydroxy-6-propanol-cyclohexyl]-5-(2-
- 214 methyloctan-2-yl)phenol).
- 215 137. AM-694 (1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole).
- 216 138. AM-2201 (1-(5-Fluoropentyl)-3-(1-naphthoyl)indole).
- 217 139. RCS-4 (1-Pentyl-3-(4-methoxybenzoyl)indole).
- 218 140. RCS-8 (1-(2-Cyclohexylethyl)-3-(2-
- 219 methoxyphenylacetyl)indole).
- 220 141. WIN55,212-2 ((R)-(+)-[2,3-Dihydro-5-methyl-3-(4-
- 221 morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-
- 222 naphthalenylmethanone).
- 223 142. WIN55,212-3 ([(3S)-2,3-Dihydro-5-methyl-3-(4-
- 224 morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-
- 225 naphthalenylmethanone).

HB 743

2024

- 226 | 143. Pentedrone (alpha-Methylaminovalerophenone).
 227 | 144. Fluoroamphetamine.
 228 | 145. Fluoromethamphetamine.
 229 | 146. Methoxetamine.
 230 | 147. Methiopropamine.
 231 | 148. Methylbuphedrone (Methyl-alpha-
 232 | methylaminobutyrophenone).
 233 | 149. APB ((2-Aminopropyl)benzofuran).
 234 | 150. APDB ((2-Aminopropyl)-2,3-dihydrobenzofuran).
 235 | 151. UR-144 (1-Pentyl-3-(2,2,3,3-
 236 | tetramethylcyclopropanoyl)indole).
 237 | 152. XLR11 (1-(5-Fluoropentyl)-3-(2,2,3,3-
 238 | tetramethylcyclopropanoyl)indole).
 239 | 153. Chloro UR-144 (1-(Chloropentyl)-3-(2,2,3,3-
 240 | tetramethylcyclopropanoyl)indole).
 241 | 154. AKB48 (N-Adamant-1-yl 1-pentylindazole-3-
 242 | carboxamide).
 243 | 155. AM-2233(1-[(N-Methyl-2-piperidinyl)methyl]-3-(2-
 244 | iodobenzoyl)indole).
 245 | 156. STS-135 (N-Adamant-1-yl 1-(5-fluoropentyl)indole-3-
 246 | carboxamide).
 247 | 157. URB-597 ((3'-(Aminocarbonyl)[1,1'-biphenyl]-3-yl)-
 248 | cyclohexylcarbamate).
 249 | 158. URB-602 ([1,1'-Biphenyl]-3-yl-carbamic acid,
 250 | cyclohexyl ester).

HB 743

2024

- 251 159. URB-754 (6-Methyl-2-[(4-methylphenyl) amino]-1-
 252 benzoxazin-4-one) .
- 253 160. 2C-D (4-Methyl-2,5-dimethoxyphenethylamine) .
- 254 161. 2C-H (2,5-Dimethoxyphenethylamine) .
- 255 162. 2C-N (4-Nitro-2,5-dimethoxyphenethylamine) .
- 256 163. 2C-P (4-(n)-Propyl-2,5-dimethoxyphenethylamine) .
- 257 164. 25I-NBOMe (4-Iodo-2,5-dimethoxy-[N-(2-
 258 methoxybenzyl)]phenethylamine) .
- 259 165. MDMA (3,4-Methylenedioxyamphetamine) .
- 260 166. PB-22 (8-Quinolinyll 1-pentylindole-3-carboxylate) .
- 261 167. Fluoro PB-22 (8-Quinolinyll 1-(fluoropentyl)indole-3-
 262 carboxylate) .
- 263 168. BB-22 (8-Quinolinyll 1-(cyclohexylmethyl)indole-3-
 264 carboxylate) .
- 265 169. Fluoro AKB48 (N-Adamant-1-yl 1-
 266 (fluoropentyl)indazole-3-carboxamide) .
- 267 170. AB-PINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-
 268 pentylindazole-3-carboxamide) .
- 269 171. AB-FUBINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-
 270 (4-fluorobenzyl)indazole-3-carboxamide) .
- 271 172. ADB-PINACA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-
 272 1-pentylindazole-3-carboxamide) .
- 273 173. Fluoro ADBICA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-
 274 yl)-1-(fluoropentyl)indole-3-carboxamide) .
- 275 174. 25B-NBOMe (4-Bromo-2,5-dimethoxy-[N-(2-

HB 743

2024

276 methoxybenzyl)]phenethylamine) .
277 175. 25C-NBOMe (4-Chloro-2,5-dimethoxy- [N- (2-
278 methoxybenzyl)]phenethylamine) .
279 176. AB-CHMINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl) -1-
280 (cyclohexylmethyl) indazole-3-carboxamide) .
281 177. FUB-PB-22 (8-Quinoliny 1- (4-fluorobenzyl) indole-3-
282 carboxylate) .
283 178. Fluoro-NNEI (N-Naphthalen-1-yl 1-
284 (fluoropentyl) indole-3-carboxamide) .
285 179. Fluoro-AMB (N- (1-Methoxy-3-methyl-1-oxobutan-2-yl) -1-
286 (fluoropentyl) indazole-3-carboxamide) .
287 180. THJ-2201 (1- (5-Fluoropentyl) -3- (1-
288 naphthoyl) indazole) .
289 181. AM-855 ((4aR,12bR) -8-Hexyl-2,5,5-trimethyl-
290 1,4,4a,8,9,10,11,12b-octahydronaphtho [3,2-c] isochromen-12-ol) .
291 182. AM-905 ((6aR,9R,10aR) -3- [(E) -Hept-1-enyl] -9-
292 (hydroxymethyl) -6,6-dimethyl-6a,7,8,9,10,10a-
293 hexahydrobenzo [c] chromen-1-ol) .
294 183. AM-906 ((6aR,9R,10aR) -3- [(Z) -Hept-1-enyl] -9-
295 (hydroxymethyl) -6,6-dimethyl-6a,7,8,9,10,10a-
296 hexahydrobenzo [c] chromen-1-ol) .
297 184. AM-2389 ((6aR,9R,10aR) -3- (1-Hexyl-cyclobut-1-yl) -
298 6a,7,8,9,10,10a-hexahydro-6,6-dimethyl-6H-dibenzo [b,d] pyran-1,9
299 diol) .
300 185. HU-243 ((6aR,8S,9S,10aR) -9- (Hydroxymethyl) -6,6-

301 dimethyl-3-(2-methyloctan-2-yl)-8,9-ditritio-7,8,10,10a-
 302 tetrahydro-6aH-benzo[c]chromen-1-ol).

303 186. HU-336 ((6aR,10aR)-6,6,9-Trimethyl-3-pentyl-
 304 6a,7,10,10a-tetrahydro-1H-benzo[c]chromene-1,4(6H)-dione).

305 187. MAPB ((2-Methylaminopropyl)benzofuran).

306 188. 5-IT (2-(1H-Indol-5-yl)-1-methyl-ethylamine).

307 189. 6-IT (2-(1H-Indol-6-yl)-1-methyl-ethylamine).

308 190. Synthetic Cannabinoids.—Unless specifically excepted
 309 or unless listed in another schedule or contained within a
 310 pharmaceutical product approved by the United States Food and
 311 Drug Administration, any material, compound, mixture, or
 312 preparation that contains any quantity of a synthetic
 313 cannabinoid found to be in any of the following chemical class
 314 descriptions, or homologues, nitrogen-heterocyclic analogs,
 315 isomers (including optical, positional, or geometric), esters,
 316 ethers, salts, and salts of homologues, nitrogen-heterocyclic
 317 analogs, isomers, esters, or ethers, whenever the existence of
 318 such homologues, nitrogen-heterocyclic analogs, isomers, esters,
 319 ethers, salts, and salts of isomers, esters, or ethers is
 320 possible within the specific chemical class or designation.
 321 Since nomenclature of these synthetically produced cannabinoids
 322 is not internationally standardized and may continually evolve,
 323 these structures or the compounds of these structures shall be
 324 included under this subparagraph, regardless of their specific
 325 numerical designation of atomic positions covered, if it can be

326 determined through a recognized method of scientific testing or
327 analysis that the substance contains properties that fit within
328 one or more of the following categories:

329 a. Tetrahydrocannabinols.—Any tetrahydrocannabinols
330 naturally contained in a plant of the genus Cannabis, the
331 synthetic equivalents of the substances contained in the plant
332 or in the resinous extracts of the genus Cannabis, or synthetic
333 substances, derivatives, and their isomers with similar chemical
334 structure and pharmacological activity, including, but not
335 limited to, Delta 9 tetrahydrocannabinols and their optical
336 isomers, Delta 8 tetrahydrocannabinols and their optical
337 isomers, Delta 6a,10a tetrahydrocannabinols and their optical
338 isomers, or any compound containing a tetrahydrobenzo[c]chromene
339 structure with substitution at either or both the 3-position or
340 9-position, with or without substitution at the 1-position with
341 hydroxyl or alkoxy groups, including, but not limited to:

342 (I) Tetrahydrocannabinol.

343 (II) HU-210 ((6aR,10aR)-9-(Hydroxymethyl)-6,6-dimethyl-3-
344 (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-
345 ol).

346 (III) HU-211 ((6aS,10aS)-9-(Hydroxymethyl)-6,6-dimethyl-3-
347 (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-
348 ol).

349 (IV) JWH-051 ((6aR,10aR)-9-(Hydroxymethyl)-6,6-dimethyl-3-
350 (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene).

HB 743

2024

351 (V) JWH-133 ((6aR,10aR)-6,6,9-Trimethyl-3-(2-methylpentan-
352 2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene).

353 (VI) JWH-057 ((6aR,10aR)-6,6,9-Trimethyl-3-(2-methyloctan-
354 2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene).

355 (VII) JWH-359 ((6aR,10aR)-1-Methoxy-6,6,9-trimethyl-3-
356 (2,3-dimethylpentan-2-yl)-6a,7,10,10a-
357 tetrahydrobenzo[c]chromene).

358 (VIII) AM-087 ((6aR,10aR)-3-(2-Methyl-6-bromohex-2-yl)-
359 6,6,9-trimethyl-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol).

360 (IX) AM-411 ((6aR,10aR)-3-(1-Adamantyl)-6,6,9-trimethyl-
361 6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol).

362 (X) Parahexyl.

363 b. Naphthoylindoles, Naphthoylindazoles,
364 Naphthoylcarbazoles, Naphthylmethylindoles,
365 Naphthylmethylindazoles, and Naphthylmethylcarbazoles.—Any
366 compound containing a naphthoylindole, naphthoylindazole,
367 naphthoylcarbazole, naphthylmethylindole,
368 naphthylmethylindazole, or naphthylmethylcarbazole structure,
369 with or without substitution on the indole, indazole, or
370 carbazole ring to any extent, whether or not substituted on the
371 naphthyl ring to any extent, including, but not limited to:

372 (I) JWH-007 (1-Pentyl-2-methyl-3-(1-naphthoyl)indole).

373 (II) JWH-011 (1-(1-Methylhexyl)-2-methyl-3-(1-
374 naphthoyl)indole).

375 (III) JWH-015 (1-Propyl-2-methyl-3-(1-naphthoyl)indole).

- 376 (IV) JWH-016 (1-Butyl-2-methyl-3-(1-naphthoyl) indole).
- 377 (V) JWH-018 (1-Pentyl-3-(1-naphthoyl) indole).
- 378 (VI) JWH-019 (1-Hexyl-3-(1-naphthoyl) indole).
- 379 (VII) JWH-020 (1-Heptyl-3-(1-naphthoyl) indole).
- 380 (VIII) JWH-022 (1-(4-Pentenyl)-3-(1-naphthoyl) indole).
- 381 (IX) JWH-071 (1-Ethyl-3-(1-naphthoyl) indole).
- 382 (X) JWH-072 (1-Propyl-3-(1-naphthoyl) indole).
- 383 (XI) JWH-073 (1-Butyl-3-(1-naphthoyl) indole).
- 384 (XII) JWH-080 (1-Butyl-3-(4-methoxy-1-naphthoyl) indole).
- 385 (XIII) JWH-081 (1-Pentyl-3-(4-methoxy-1-naphthoyl) indole).
- 386 (XIV) JWH-098 (1-Pentyl-2-methyl-3-(4-methoxy-1-
- 387 naphthoyl) indole).
- 388 (XV) JWH-116 (1-Pentyl-2-ethyl-3-(1-naphthoyl) indole).
- 389 (XVI) JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl) indole).
- 390 (XVII) JWH-149 (1-Pentyl-2-methyl-3-(4-methyl-1-
- 391 naphthoyl) indole).
- 392 (XVIII) JWH-164 (1-Pentyl-3-(7-methoxy-1-
- 393 naphthoyl) indole).
- 394 (XIX) JWH-175 (1-Pentyl-3-(1-naphthylmethyl) indole).
- 395 (XX) JWH-180 (1-Propyl-3-(4-propyl-1-naphthoyl) indole).
- 396 (XXI) JWH-182 (1-Pentyl-3-(4-propyl-1-naphthoyl) indole).
- 397 (XXII) JWH-184 (1-Pentyl-3-[(4-methyl)-1-
- 398 naphthylmethyl] indole).
- 399 (XXIII) JWH-193 (1-[2-(4-Morpholinyl) ethyl]-3-(4-methyl-1-
- 400 naphthoyl) indole).

HB 743

2024

401 (XXIV) JWH-198 (1-[2-(4-Morpholinyl)ethyl]-3-(4-methoxy-1-
 402 naphthoyl)indole).
 403 (XXV) JWH-200 (1-[2-(4-Morpholinyl)ethyl]-3-(1-
 404 naphthoyl)indole).
 405 (XXVI) JWH-210 (1-Pentyl-3-(4-ethyl-1-naphthoyl)indole).
 406 (XXVII) JWH-387 (1-Pentyl-3-(4-bromo-1-naphthoyl)indole).
 407 (XXVIII) JWH-398 (1-Pentyl-3-(4-chloro-1-
 408 naphthoyl)indole).
 409 (XXIX) JWH-412 (1-Pentyl-3-(4-fluoro-1-naphthoyl)indole).
 410 (XXX) JWH-424 (1-Pentyl-3-(8-bromo-1-naphthoyl)indole).
 411 (XXXI) AM-1220 (1-[(1-Methyl-2-piperidinyl)methyl]-3-(1-
 412 naphthoyl)indole).
 413 (XXXII) AM-1235 (1-(5-Fluoropentyl)-6-nitro-3-(1-
 414 naphthoyl)indole).
 415 (XXXIII) AM-2201 (1-(5-Fluoropentyl)-3-(1-
 416 naphthoyl)indole).
 417 (XXXIV) Chloro JWH-018 (1-(Chloropentyl)-3-(1-
 418 naphthoyl)indole).
 419 (XXXV) Bromo JWH-018 (1-(Bromopentyl)-3-(1-
 420 naphthoyl)indole).
 421 (XXXVI) AM-2232 (1-(4-Cyanobutyl)-3-(1-naphthoyl)indole).
 422 (XXXVII) THJ-2201 (1-(5-Fluoropentyl)-3-(1-
 423 naphthoyl)indazole).
 424 (XXXVIII) MAM-2201 (1-(5-Fluoropentyl)-3-(4-methyl-1-
 425 naphthoyl)indole).

HB 743

2024

426 (XXXIX) EAM-2201 (1-(5-Fluoropentyl)-3-(4-ethyl-1-
427 naphthoyl)indole).

428 (XL) EG-018 (9-Pentyl-3-(1-naphthoyl)carbazole).

429 (XLI) EG-2201 (9-(5-Fluoropentyl)-3-(1-
430 naphthoyl)carbazole).

431 c. Naphthoylpyrroles.—Any compound containing a
432 naphthoylpyrrole structure, with or without substitution on the
433 pyrrole ring to any extent, whether or not substituted on the
434 naphthyl ring to any extent, including, but not limited to:

435 (I) JWH-030 (1-Pentyl-3-(1-naphthoyl)pyrrole).

436 (II) JWH-031 (1-Hexyl-3-(1-naphthoyl)pyrrole).

437 (III) JWH-145 (1-Pentyl-5-phenyl-3-(1-naphthoyl)pyrrole).

438 (IV) JWH-146 (1-Heptyl-5-phenyl-3-(1-naphthoyl)pyrrole).

439 (V) JWH-147 (1-Hexyl-5-phenyl-3-(1-naphthoyl)pyrrole).

440 (VI) JWH-307 (1-Pentyl-5-(2-fluorophenyl)-3-(1-
441 naphthoyl)pyrrole).

442 (VII) JWH-309 (1-Pentyl-5-(1-naphthalenyl)-3-(1-
443 naphthoyl)pyrrole).

444 (VIII) JWH-368 (1-Pentyl-5-(3-fluorophenyl)-3-(1-
445 naphthoyl)pyrrole).

446 (IX) JWH-369 (1-Pentyl-5-(2-chlorophenyl)-3-(1-
447 naphthoyl)pyrrole).

448 (X) JWH-370 (1-Pentyl-5-(2-methylphenyl)-3-(1-
449 naphthoyl)pyrrole).

450 d. Naphthylmethylenindenes.—Any compound containing a

HB 743

2024

451 naphthylmethylenindene structure, with or without substitution
452 at the 3-position of the indene ring to any extent, whether or
453 not substituted on the naphthyl ring to any extent, including,
454 but not limited to, JWH-176 (3-Pentyl-1-
455 (naphthylmethylene)indene).

456 e. Phenylacetylindoles and Phenylacetylindazoles.—Any
457 compound containing a phenylacetylindole or phenylacetylindazole
458 structure, with or without substitution on the indole or
459 indazole ring to any extent, whether or not substituted on the
460 phenyl ring to any extent, including, but not limited to:

- 461 (I) JWH-167 (1-Pentyl-3-(phenylacetyl)indole).
462 (II) JWH-201 (1-Pentyl-3-(4-methoxyphenylacetyl)indole).
463 (III) JWH-203 (1-Pentyl-3-(2-chlorophenylacetyl)indole).
464 (IV) JWH-250 (1-Pentyl-3-(2-methoxyphenylacetyl)indole).
465 (V) JWH-251 (1-Pentyl-3-(2-methylphenylacetyl)indole).
466 (VI) JWH-302 (1-Pentyl-3-(3-methoxyphenylacetyl)indole).
467 (VII) Cannabipiperidiethanone.
468 (VIII) RCS-8 (1-(2-Cyclohexylethyl)-3-(2-
469 methoxyphenylacetyl)indole).

470 f. Cyclohexylphenols.—Any compound containing a
471 cyclohexylphenol structure, with or without substitution at the
472 5-position of the phenolic ring to any extent, whether or not
473 substituted on the cyclohexyl ring to any extent, including, but
474 not limited to:

- 475 (I) CP 47,497 (2-(3-Hydroxycyclohexyl)-5-(2-methyloctan-2-

HB 743

2024

476 yl)phenol).

477 (II) Cannabicyclohexanol (CP 47,497 dimethyloctyl (C8)

478 homologue).

479 (III) CP-55,940 (2-(3-Hydroxy-6-propanol-cyclohexyl)-5-(2-

480 methyloctan-2-yl)phenol).

481 g. Benzoylindoles and Benzoylindazoles.—Any compound

482 containing a benzoylindole or benzoylindazole structure, with or

483 without substitution on the indole or indazole ring to any

484 extent, whether or not substituted on the phenyl ring to any

485 extent, including, but not limited to:

486 (I) AM-679 (1-Pentyl-3-(2-iodobenzoyl)indole).

487 (II) AM-694 (1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole).

488 (III) AM-1241 (1-[(N-Methyl-2-piperidinyl)methyl]-3-(2-

489 iodo-5-nitrobenzoyl)indole).

490 (IV) Pravadoline (1-[2-(4-Morpholinyl)ethyl]-2-methyl-3-

491 (4-methoxybenzoyl)indole).

492 (V) AM-2233 (1-[(N-Methyl-2-piperidinyl)methyl]-3-(2-

493 iodobenzoyl)indole).

494 (VI) RCS-4 (1-Pentyl-3-(4-methoxybenzoyl)indole).

495 (VII) RCS-4 C4 homologue (1-Butyl-3-(4-

496 methoxybenzoyl)indole).

497 (VIII) AM-630 (1-[2-(4-Morpholinyl)ethyl]-2-methyl-6-iodo-

498 3-(4-methoxybenzoyl)indole).

499 h. Tetramethylcyclopropanoylindoles and

500 Tetramethylcyclopropanoylindazoles.—Any compound containing a

501 tetramethylcyclopropanoylindole or
 502 tetramethylcyclopropanoylindazole structure, with or without
 503 substitution on the indole or indazole ring to any extent,
 504 whether or not substituted on the tetramethylcyclopropyl group
 505 to any extent, including, but not limited to:

506 (I) UR-144 (1-Pentyl-3-(2,2,3,3-
 507 tetramethylcyclopropanoyl)indole).

508 (II) XLR11 (1-(5-Fluoropentyl)-3-(2,2,3,3-
 509 tetramethylcyclopropanoyl)indole).

510 (III) Chloro UR-144 (1-(Chloropentyl)-3-(2,2,3,3-
 511 tetramethylcyclopropanoyl)indole).

512 (IV) A-796,260 (1-[2-(4-Morpholinyl)ethyl]-3-(2,2,3,3-
 513 tetramethylcyclopropanoyl)indole).

514 (V) A-834,735 (1-[4-(Tetrahydropyranyl)methyl]-3-(2,2,3,3-
 515 tetramethylcyclopropanoyl)indole).

516 (VI) M-144 (1-(5-Fluoropentyl)-2-methyl-3-(2,2,3,3-
 517 tetramethylcyclopropanoyl)indole).

518 (VII) FUB-144 (1-(4-Fluorobenzyl)-3-(2,2,3,3-
 519 tetramethylcyclopropanoyl)indole).

520 (VIII) FAB-144 (1-(5-Fluoropentyl)-3-(2,2,3,3-
 521 tetramethylcyclopropanoyl)indazole).

522 (IX) XLR12 (1-(4,4,4-Trifluorobutyl)-3-(2,2,3,3-
 523 tetramethylcyclopropanoyl)indole).

524 (X) AB-005 (1-[(1-Methyl-2-piperidinyl)methyl]-3-(2,2,3,3-
 525 tetramethylcyclopropanoyl)indole).

526 i. Adamantoylindoles, Adamantoylindazoles, Adamantylindole
 527 carboxamides, and Adamantylindazole carboxamides.—Any compound
 528 containing an adamantoyl indole, adamantoyl indazole, adamantyl
 529 indole carboxamide, or adamantyl indazole carboxamide structure,
 530 with or without substitution on the indole or indazole ring to
 531 any extent, whether or not substituted on the adamantyl ring to
 532 any extent, including, but not limited to:

533 (I) AKB48 (N-Adamant-1-yl 1-pentylindazole-3-carboxamide).

534 (II) Fluoro AKB48 (N-Adamant-1-yl 1-
 535 (fluoropentyl)indazole-3-carboxamide).

536 (III) STS-135 (N-Adamant-1-yl 1-(5-fluoropentyl)indole-3-
 537 carboxamide).

538 (IV) AM-1248 (1-(1-Methylpiperidine)methyl-3-(1-
 539 adamantoyl)indole).

540 (V) AB-001 (1-Pentyl-3-(1-adamantoyl)indole).

541 (VI) APICA (N-Adamant-1-yl 1-pentylindole-3-carboxamide).

542 (VII) Fluoro AB-001 (1-(Fluoropentyl)-3-(1-
 543 adamantoyl)indole).

544 j. Quinolinyndolecarboxylates,
 545 Quinolinyndazolecarboxylates, Quinolinyndolecarboxamides,
 546 and Quinolinyndazolecarboxamides.—Any compound containing a
 547 quinolinyndole carboxylate, quinolinyndazole carboxylate,
 548 isoquinolinyndole carboxylate, isoquinolinyndazole
 549 carboxylate, quinolinyndole carboxamide, quinolinyndazole
 550 carboxamide, isoquinolinyndole carboxamide, or

HB 743

2024

551 isoquinolinylindazole carboxamide structure, with or without
552 substitution on the indole or indazole ring to any extent,
553 whether or not substituted on the quinoline or isoquinoline ring
554 to any extent, including, but not limited to:

555 (I) PB-22 (8-Quinoliny 1-pentylindole-3-carboxylate).

556 (II) Fluoro PB-22 (8-Quinoliny 1-(fluoropentyl)indole-3-
557 carboxylate).

558 (III) BB-22 (8-Quinoliny 1-(cyclohexylmethyl)indole-3-
559 carboxylate).

560 (IV) FUB-PB-22 (8-Quinoliny 1-(4-fluorobenzyl)indole-3-
561 carboxylate).

562 (V) NPB-22 (8-Quinoliny 1-pentylindazole-3-carboxylate).

563 (VI) Fluoro NPB-22 (8-Quinoliny 1-(fluoropentyl)indazole-
564 3-carboxylate).

565 (VII) FUB-NPB-22 (8-Quinoliny 1-(4-fluorobenzyl)indazole-
566 3-carboxylate).

567 (VIII) THJ (8-Quinoliny 1-pentylindazole-3-carboxamide).

568 (IX) Fluoro THJ (8-Quinoliny 1-(fluoropentyl)indazole-3-
569 carboxamide).

570 k. Naphthylindolecarboxylates and
571 Naphthylindazolecarboxylates.—Any compound containing a
572 naphthylindole carboxylate or naphthylindazole carboxylate
573 structure, with or without substitution on the indole or
574 indazole ring to any extent, whether or not substituted on the
575 naphthyl ring to any extent, including, but not limited to:

HB 743

2024

576 (I) NM-2201 (1-Naphthalenyl 1-(5-fluoropentyl)indole-3-
577 carboxylate).

578 (II) SDB-005 (1-Naphthalenyl 1-pentylindazole-3-
579 carboxylate).

580 (III) Fluoro SDB-005 (1-Naphthalenyl 1-
581 (fluoropentyl)indazole-3-carboxylate).

582 (IV) FDU-PB-22 (1-Naphthalenyl 1-(4-fluorobenzyl)indole-3-
583 carboxylate).

584 (V) 3-CAF (2-Naphthalenyl 1-(2-fluorophenyl)indazole-3-
585 carboxylate).

586 1. Naphthylindole carboxamides and Naphthylindazole
587 carboxamides.—Any compound containing a naphthylindole
588 carboxamide or naphthylindazole carboxamide structure, with or
589 without substitution on the indole or indazole ring to any
590 extent, whether or not substituted on the naphthyl ring to any
591 extent, including, but not limited to:

592 (I) NNEI (N-Naphthalen-1-yl 1-pentylindole-3-carboxamide).

593 (II) Fluoro-NNEI (N-Naphthalen-1-yl 1-
594 (fluoropentyl)indole-3-carboxamide).

595 (III) Chloro-NNEI (N-Naphthalen-1-yl 1-
596 (chloropentyl)indole-3-carboxamide).

597 (IV) MN-18 (N-Naphthalen-1-yl 1-pentylindazole-3-
598 carboxamide).

599 (V) Fluoro MN-18 (N-Naphthalen-1-yl 1-
600 (fluoropentyl)indazole-3-carboxamide).

HB 743

2024

601 m. Alkylcarbonyl indole carboxamides, Alkylcarbonyl
602 indazole carboxamides, Alkylcarbonyl indole carboxylates, and
603 Alkylcarbonyl indazole carboxylates.—Any compound containing an
604 alkylcarbonyl group, including 1-amino-3-methyl-1-oxobutan-2-yl,
605 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-amino-1-oxo-3-
606 phenylpropan-2-yl, 1-methoxy-1-oxo-3-phenylpropan-2-yl, with an
607 indole carboxamide, indazole carboxamide, indole carboxylate, or
608 indazole carboxylate, with or without substitution on the indole
609 or indazole ring to any extent, whether or not substituted on
610 the alkylcarbonyl group to any extent, including, but not
611 limited to:

612 (I) ADBICA, (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-
613 pentylindole-3-carboxamide).

614 (II) Fluoro ADBICA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-
615 yl)-1-(fluoropentyl)indole-3-carboxamide).

616 (III) Fluoro ABICA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-
617 1-(fluoropentyl)indole-3-carboxamide).

618 (IV) AB-PINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-
619 pentylindazole-3-carboxamide).

620 (V) Fluoro AB-PINACA (N-(1-Amino-3-methyl-1-oxobutan-2-
621 yl)-1-(fluoropentyl)indazole-3-carboxamide).

622 (VI) ADB-PINACA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-
623 1-pentylindazole-3-carboxamide).

624 (VII) Fluoro ADB-PINACA (N-(1-Amino-3,3-dimethyl-1-
625 oxobutan-2-yl)-1-(fluoropentyl)indazole-3-carboxamide).

HB 743

2024

- 626 (VIII) AB-FUBINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-
 627 1-(4-fluorobenzyl)indazole-3-carboxamide).
- 628 (IX) ADB-FUBINACA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-
 629 yl)-1-(4-fluorobenzyl)indazole-3-carboxamide).
- 630 (X) AB-CHMINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-
 631 (cyclohexylmethyl)indazole-3-carboxamide).
- 632 (XI) MA-CHMINACA (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-
 633 1-(cyclohexylmethyl)indazole-3-carboxamide).
- 634 (XII) MAB-CHMINACA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-
 635 yl)-1-(cyclohexylmethyl)indazole-3-carboxamide).
- 636 (XIII) AMB (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1-
 637 pentylindazole-3-carboxamide).
- 638 (XIV) Fluoro-AMB (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-
 639 1-(fluoropentyl)indazole-3-carboxamide).
- 640 (XV) FUB-AMB (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1-(4-
 641 fluorobenzyl)indazole-3-carboxamide).
- 642 (XVI) MDMB-CHMINACA (N-(1-Methoxy-3,3-dimethyl-1-oxobutan-
 643 2-yl)-1-(cyclohexylmethyl)indazole-3-carboxamide).
- 644 (XVII) MDMB-FUBINACA (N-(1-Methoxy-3,3-dimethyl-1-
 645 oxobutan-2-yl)-1-(4-fluorobenzyl)indazole-3-carboxamide).
- 646 (XVIII) MDMB-CHMICA (N-(1-Methoxy-3,3-dimethyl-1-oxobutan-
 647 2-yl)-1-(cyclohexylmethyl)indole-3-carboxamide).
- 648 (XIX) PX-1 (N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(5-
 649 fluoropentyl)indole-3-carboxamide).
- 650 (XX) PX-2 (N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(5-

HB 743

2024

651 fluoropentyl)indazole-3-carboxamide).

652 (XXI) PX-3 (N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-
653 (cyclohexylmethyl)indazole-3-carboxamide).

654 (XXII) PX-4 (N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(4-
655 fluorobenzyl)indazole-3-carboxamide).

656 (XXIII) MO-CHMINACA (N-(1-Methoxy-3,3-dimethyl-1-oxobutan-
657 2-yl)-1-(cyclohexylmethyl)indazole-3-carboxylate).

658 n. Cumylindolecarboxamides and Cumylindazolecarboxamides.—
659 Any compound containing a N-(2-phenylpropan-2-yl) indole
660 carboxamide or N-(2-phenylpropan-2-yl) indazole carboxamide
661 structure, with or without substitution on the indole or
662 indazole ring to any extent, whether or not substituted on the
663 phenyl ring of the cumyl group to any extent, including, but not
664 limited to:

665 (I) CUMYL-PICA (N-(2-Phenylpropan-2-yl)-1-pentylindole-3-
666 carboxamide).

667 (II) Fluoro CUMYL-PICA (N-(2-Phenylpropan-2-yl)-1-
668 (fluoropentyl)indole-3-carboxamide).

669 o. Other Synthetic Cannabinoids.—Any material, compound,
670 mixture, or preparation that contains any quantity of a
671 Synthetic Cannabinoid, as described in sub-subparagraphs a.-n.:

672 (I) With or without modification or replacement of a
673 carbonyl, carboxamide, alkylene, alkyl, or carboxylate linkage
674 between either two core rings, or linkage between a core ring
675 and group structure, with or without the addition of a carbon or

676 replacement of a carbon;

677 (II) With or without replacement of a core ring or group

678 structure, whether or not substituted on the ring or group

679 structures to any extent; and

680 (III) Is a cannabinoid receptor agonist, unless

681 specifically excepted or unless listed in another schedule or

682 contained within a pharmaceutical product approved by the United

683 States Food and Drug Administration.

684 191. Substituted Cathinones.—Unless specifically excepted,

685 listed in another schedule, or contained within a pharmaceutical

686 product approved by the United States Food and Drug

687 Administration, any material, compound, mixture, or preparation,

688 including its salts, isomers, esters, or ethers, and salts of

689 isomers, esters, or ethers, whenever the existence of such salts

690 is possible within any of the following specific chemical

691 designations:

692 a. Any compound containing a 2-amino-1-phenyl-1-propanone

693 structure;

694 b. Any compound containing a 2-amino-1-naphthyl-1-

695 propanone structure; or

696 c. Any compound containing a 2-amino-1-thiophenyl-1-

697 propanone structure,

698 whether or not the compound is further modified:

699 (I) With or without substitution on the ring system to any

700 extent with alkyl, alkylthio, thio, fused alkylenedioxy, alkoxy,

701 haloalkyl, hydroxyl, nitro, fused furan, fused benzofuran, fused
 702 dihydrofuran, fused tetrahydropyran, fused alkyl ring, or halide
 703 substituents;

704 (II) With or without substitution at the 3-propanone
 705 position with an alkyl substituent or removal of the methyl
 706 group at the 3-propanone position;

707 (III) With or without substitution at the 2-amino nitrogen
 708 atom with alkyl, dialkyl, acetyl, or benzyl groups, whether or
 709 not further substituted in the ring system; or

710 (IV) With or without inclusion of the 2-amino nitrogen
 711 atom in a cyclic structure, including, but not limited to:

- 712 (A) Methcathinone.
- 713 (B) Ethcathinone.
- 714 (C) Methylone (3,4-Methylenedioxy-methcathinone).
- 715 (D) 2,3-Methylenedioxy-methcathinone.
- 716 (E) MDPV (3,4-Methylenedioxy-pyrovalerone).
- 717 (F) Methylmethcathinone.
- 718 (G) Methoxymethcathinone.
- 719 (H) Fluoromethcathinone.
- 720 (I) Methylethcathinone.
- 721 (J) Butylone (3,4-Methylenedioxy-alpha-
- 722 methylaminobutyrophenone).
- 723 (K) Ethylone (3,4-Methylenedioxy-N-ethylcathinone).
- 724 (L) BMDP (3,4-Methylenedioxy-N-benzylcathinone).
- 725 (M) Naphyrone (Naphthylpyrovalerone).

HB 743

2024

- 726 (N) Bromomethcathinone.
- 727 (O) Buphedrone (alpha-Methylaminobutyrophenone).
- 728 (P) Eutylone (3,4-Methylenedioxy-alpha-
- 729 ethylaminobutyrophenone).
- 730 (Q) Dimethylcathinone.
- 731 (R) Dimethylmethcathinone.
- 732 (S) Pentylone (3,4-Methylenedioxy-alpha-
- 733 methylaminovalerophenone).
- 734 (T) Pentedrone (alpha-Methylaminovalerophenone).
- 735 (U) MDPPP (3,4-Methylenedioxy-alpha-
- 736 pyrrolidinopropiophenone).
- 737 (V) MDPBP (3,4-Methylenedioxy-alpha-
- 738 pyrrolidinobutyrophenone).
- 739 (W) MPPP (Methyl-alpha-pyrrolidinopropiophenone).
- 740 (X) PPP (Pyrrolidinopropiophenone).
- 741 (Y) PVP (Pyrrolidinovalerophenone) or
- 742 (Pyrrolidinopentiophenone).
- 743 (Z) MOPPP (Methoxy-alpha-pyrrolidinopropiophenone).
- 744 (AA) MPHP (Methyl-alpha-pyrrolidinohexanophenone).
- 745 (BB) F-MABP (Fluoromethylaminobutyrophenone).
- 746 (CC) Me-EABP (Methylethylaminobutyrophenone).
- 747 (DD) PBP (Pyrrolidinobutyrophenone).
- 748 (EE) MeO-PBP (Methoxypyrrolidinobutyrophenone).
- 749 (FF) Et-PBP (Ethylpyrrolidinobutyrophenone).
- 750 (GG) 3-Me-4-MeO-MCAT (3-Methyl-4-Methoxymethcathinone).

HB 743

2024

- 751 (HH) Dimethylone (3,4-Methylenedioxy-N,N-
- 752 dimethylcathinone).
- 753 (II) 3,4-Methylenedioxy-N,N-diethylcathinone.
- 754 (JJ) 3,4-Methylenedioxy-N-acetylcathinone.
- 755 (KK) 3,4-Methylenedioxy-N-acetylmethcathinone.
- 756 (LL) 3,4-Methylenedioxy-N-acetylethcathinone.
- 757 (MM) Methylbuphedrone (Methyl-alpha-
- 758 methylaminobutyrophenone).
- 759 (NN) Methyl-alpha-methylaminohexanophenone.
- 760 (OO) N-Ethyl-N-methylcathinone.
- 761 (PP) PHP (Pyrrolidinohexanophenone).
- 762 (QQ) PV8 (Pyrrolidinoheptanophenone).
- 763 (RR) Chloromethcathinone.
- 764 (SS) 4-Bromo-2,5-dimethoxy-alpha-aminoacetophenone.
- 765 192. Substituted Phenethylamines.—Unless specifically
- 766 excepted or unless listed in another schedule, or contained
- 767 within a pharmaceutical product approved by the United States
- 768 Food and Drug Administration, any material, compound, mixture,
- 769 or preparation, including its salts, isomers, esters, or ethers,
- 770 and salts of isomers, esters, or ethers, whenever the existence
- 771 of such salts is possible within any of the following specific
- 772 chemical designations, any compound containing a phenethylamine
- 773 structure, without a beta-keto group, and without a benzyl group
- 774 attached to the amine group, whether or not the compound is
- 775 further modified with or without substitution on the phenyl ring

776 | to any extent with alkyl, alkylthio, nitro, alkoxy, thio,
 777 | halide, fused alkylenedioxy, fused furan, fused benzofuran,
 778 | fused dihydrofuran, or fused tetrahydropyran substituents,
 779 | whether or not further substituted on a ring to any extent, with
 780 | or without substitution at the alpha or beta position by any
 781 | alkyl substituent, with or without substitution at the nitrogen
 782 | atom, and with or without inclusion of the 2-amino nitrogen atom
 783 | in a cyclic structure, including, but not limited to:

- 784 | a. 2C-B (4-Bromo-2,5-dimethoxyphenethylamine).
- 785 | b. 2C-E (4-Ethyl-2,5-dimethoxyphenethylamine).
- 786 | c. 2C-T-4 (4-Isopropylthio-2,5-dimethoxyphenethylamine).
- 787 | d. 2C-C (4-Chloro-2,5-dimethoxyphenethylamine).
- 788 | e. 2C-T (4-Methylthio-2,5-dimethoxyphenethylamine).
- 789 | f. 2C-T-2 (4-Ethylthio-2,5-dimethoxyphenethylamine).
- 790 | g. 2C-T-7 (4-(n)-Propylthio-2,5-dimethoxyphenethylamine).
- 791 | h. 2C-I (4-Iodo-2,5-dimethoxyphenethylamine).
- 792 | i. 2C-D (4-Methyl-2,5-dimethoxyphenethylamine).
- 793 | j. 2C-H (2,5-Dimethoxyphenethylamine).
- 794 | k. 2C-N (4-Nitro-2,5-dimethoxyphenethylamine).
- 795 | l. 2C-P (4-(n)-Propyl-2,5-dimethoxyphenethylamine).
- 796 | m. MDMA (3,4-Methylenedioxyamphetamine).
- 797 | n. MBDB (Methylbenzodioxolylbutanamine) or (3,4-
 798 | Methyleneoxy-N-methylbutanamine).
- 799 | o. MDA (3,4-Methylenedioxyamphetamine).
- 800 | p. 2,5-Dimethoxyamphetamine.

- 801 q. Fluoroamphetamine.
- 802 r. Fluoromethamphetamine.
- 803 s. MDEA (3,4-Methylenedioxy-N-ethylamphetamine).
- 804 t. DOB (4-Bromo-2,5-dimethoxyamphetamine).
- 805 u. DOC (4-Chloro-2,5-dimethoxyamphetamine).
- 806 v. DOET (4-Ethyl-2,5-dimethoxyamphetamine).
- 807 w. DOI (4-Iodo-2,5-dimethoxyamphetamine).
- 808 x. DOM (4-Methyl-2,5-dimethoxyamphetamine).
- 809 y. PMA (4-Methoxyamphetamine).
- 810 z. N-Ethylamphetamine.
- 811 aa. 3,4-Methylenedioxy-N-hydroxyamphetamine.
- 812 bb. 5-Methoxy-3,4-methylenedioxyamphetamine.
- 813 cc. PMMA (4-Methoxymethamphetamine).
- 814 dd. N,N-Dimethylamphetamine.
- 815 ee. 3,4,5-Trimethoxyamphetamine.
- 816 ff. 4-APB (4-(2-Aminopropyl)benzofuran).
- 817 gg. 5-APB (5-(2-Aminopropyl)benzofuran).
- 818 hh. 6-APB (6-(2-Aminopropyl)benzofuran).
- 819 ii. 7-APB (7-(2-Aminopropyl)benzofuran).
- 820 jj. 4-APDB (4-(2-Aminopropyl)-2,3-dihydrobenzofuran).
- 821 kk. 5-APDB (5-(2-Aminopropyl)-2,3-dihydrobenzofuran).
- 822 ll. 6-APDB (6-(2-Aminopropyl)-2,3-dihydrobenzofuran).
- 823 mm. 7-APDB (7-(2-Aminopropyl)-2,3-dihydrobenzofuran).
- 824 nn. 4-MAPB (4-(2-Methylaminopropyl)benzofuran).
- 825 oo. 5-MAPB (5-(2-Methylaminopropyl)benzofuran).

HB 743

2024

826 pp. 6-MAPB (6-(2-Methylaminopropyl)benzofuran).
 827 qq. 7-MAPB (7-(2-Methylaminopropyl)benzofuran).
 828 rr. 5-EAPB (5-(2-Ethylaminopropyl)benzofuran).
 829 ss. 5-MAPDB (5-(2-Methylaminopropyl)-2,3-
 830 dihydrobenzofuran),

831
 832 which does not include phenethylamine, mescaline as described in
 833 subparagraph 20., substituted cathinones as described in
 834 subparagraph 191., N-Benzyl phenethylamine compounds as
 835 described in subparagraph 193., or methamphetamine as described
 836 in subparagraph (2)(c)5.

837 193. N-Benzyl Phenethylamine Compounds.—Unless
 838 specifically excepted or unless listed in another schedule, or
 839 contained within a pharmaceutical product approved by the United
 840 States Food and Drug Administration, any material, compound,
 841 mixture, or preparation, including its salts, isomers, esters,
 842 or ethers, and salts of isomers, esters, or ethers, whenever the
 843 existence of such salts is possible within any of the following
 844 specific chemical designations, any compound containing a
 845 phenethylamine structure without a beta-keto group, with
 846 substitution on the nitrogen atom of the amino group with a
 847 benzyl substituent, with or without substitution on the phenyl
 848 or benzyl ring to any extent with alkyl, alkoxy, thio,
 849 alkylthio, halide, fused alkylenedioxy, fused furan, fused
 850 benzofuran, or fused tetrahydropyran substituents, whether or

HB 743

2024

851 not further substituted on a ring to any extent, with or without
852 substitution at the alpha position by any alkyl substituent,
853 including, but not limited to:

854 a. 25B-NBOMe (4-Bromo-2,5-dimethoxy-[N-(2-
855 methoxybenzyl)]phenethylamine).

856 b. 25B-NBOH (4-Bromo-2,5-dimethoxy-[N-(2-
857 hydroxybenzyl)]phenethylamine).

858 c. 25B-NBF (4-Bromo-2,5-dimethoxy-[N-(2-
859 fluorobenzyl)]phenethylamine).

860 d. 25B-NBMD (4-Bromo-2,5-dimethoxy-[N-(2,3-
861 methylenedioxybenzyl)]phenethylamine).

862 e. 25I-NBOMe (4-Iodo-2,5-dimethoxy-[N-(2-
863 methoxybenzyl)]phenethylamine).

864 f. 25I-NBOH (4-Iodo-2,5-dimethoxy-[N-(2-
865 hydroxybenzyl)]phenethylamine).

866 g. 25I-NBF (4-Iodo-2,5-dimethoxy-[N-(2-
867 fluorobenzyl)]phenethylamine).

868 h. 25I-NBMD (4-Iodo-2,5-dimethoxy-[N-(2,3-
869 methylenedioxybenzyl)]phenethylamine).

870 i. 25T2-NBOMe (4-Methylthio-2,5-dimethoxy-[N-(2-
871 methoxybenzyl)]phenethylamine).

872 j. 25T4-NBOMe (4-Isopropylthio-2,5-dimethoxy-[N-(2-
873 methoxybenzyl)]phenethylamine).

874 k. 25T7-NBOMe (4-(n)-Propylthio-2,5-dimethoxy-[N-(2-
875 methoxybenzyl)]phenethylamine).

HB 743

2024

- 876 | 1. 25C-NBOMe (4-Chloro-2,5-dimethoxy-[N-(2-
- 877 | methoxybenzyl)]phenethylamine).
- 878 | m. 25C-NBOH (4-Chloro-2,5-dimethoxy-[N-(2-
- 879 | hydroxybenzyl)]phenethylamine).
- 880 | n. 25C-NBF (4-Chloro-2,5-dimethoxy-[N-(2-
- 881 | fluorobenzyl)]phenethylamine).
- 882 | o. 25C-NBMD (4-Chloro-2,5-dimethoxy-[N-(2,3-
- 883 | methylenedioxybenzyl)]phenethylamine).
- 884 | p. 25H-NBOMe (2,5-Dimethoxy-[N-(2-
- 885 | methoxybenzyl)]phenethylamine).
- 886 | q. 25H-NBOH (2,5-Dimethoxy-[N-(2-
- 887 | hydroxybenzyl)]phenethylamine).
- 888 | r. 25H-NBF (2,5-Dimethoxy-[N-(2-
- 889 | fluorobenzyl)]phenethylamine).
- 890 | s. 25D-NBOMe (4-Methyl-2,5-dimethoxy-[N-(2-
- 891 | methoxybenzyl)]phenethylamine),

892 |

893 | which does not include substituted cathinones as described in

894 | subparagraph 191.

895 | 194. Substituted Tryptamines.—Unless specifically excepted

896 | or unless listed in another schedule, or contained within a

897 | pharmaceutical product approved by the United States Food and

898 | Drug Administration, any material, compound, mixture, or

899 | preparation containing a 2-(1H-indol-3-yl)ethanamine, for

900 | example tryptamine, structure with or without mono- or di-

901 substitution of the amine nitrogen with alkyl or alkenyl groups,
 902 or by inclusion of the amino nitrogen atom in a cyclic
 903 structure, whether or not substituted at the alpha position with
 904 an alkyl group, whether or not substituted on the indole ring to
 905 any extent with any alkyl, alkoxy, halo, hydroxyl, or acetoxy
 906 groups, including, but not limited to:

- 907 a. Alpha-Ethyltryptamine.
- 908 b. Bufotenine.
- 909 c. DET (Diethyltryptamine).
- 910 d. DMT (Dimethyltryptamine).
- 911 e. MET (N-Methyl-N-ethyltryptamine).
- 912 f. DALT (N,N-Diallyltryptamine).
- 913 g. EiPT (N-Ethyl-N-isopropyltryptamine).
- 914 h. MiPT (N-Methyl-N-isopropyltryptamine).
- 915 i. 5-Hydroxy-AMT (5-Hydroxy-alpha-methyltryptamine).
- 916 j. 5-Hydroxy-N-methyltryptamine.
- 917 k. 5-MeO-MiPT (5-Methoxy-N-methyl-N-isopropyltryptamine).
- 918 l. 5-MeO-AMT (5-Methoxy-alpha-methyltryptamine).
- 919 m. Methyltryptamine.
- 920 n. 5-MeO-DMT (5-Methoxy-N,N-dimethyltryptamine).
- 921 o. 5-Me-DMT (5-Methyl-N,N-dimethyltryptamine).
- 922 p. 5-MeO-DiPT (5-Methoxy-N,N-Diisopropyltryptamine).
- 923 q. DiPT (N,N-Diisopropyltryptamine).
- 924 r. DPT (N,N-Dipropyltryptamine).
- 925 s. 4-Hydroxy-DiPT (4-Hydroxy-N,N-diisopropyltryptamine).

- 926 t. 5-MeO-DALT (5-Methoxy-N,N-Diallyltryptamine).
- 927 u. 4-AcO-DMT (4-Acetoxy-N,N-dimethyltryptamine).
- 928 v. 4-AcO-DiPT (4-Acetoxy-N,N-diisopropyltryptamine).
- 929 w. 4-Hydroxy-DET (4-Hydroxy-N,N-diethyltryptamine).
- 930 x. 4-Hydroxy-MET (4-Hydroxy-N-methyl-N-ethyltryptamine).
- 931 y. 4-Hydroxy-MiPT (4-Hydroxy-N-methyl-N-
- 932 isopropyltryptamine).
- 933 z. Methyl-alpha-ethyltryptamine.
- 934 aa. Bromo-DALT (Bromo-N,N-diallyltryptamine),

935
 936 which does not include tryptamine, psilocyn as described in
 937 subparagraph 34., or psilocybin as described in subparagraph 33.

938 195. Substituted Phenylcyclohexylamines.—Unless
 939 specifically excepted or unless listed in another schedule, or
 940 contained within a pharmaceutical product approved by the United
 941 States Food and Drug Administration, any material, compound,
 942 mixture, or preparation containing a phenylcyclohexylamine
 943 structure, with or without any substitution on the phenyl ring,
 944 any substitution on the cyclohexyl ring, any replacement of the
 945 phenyl ring with a thiophenyl or benzothiophenyl ring, with or
 946 without substitution on the amine with alkyl, dialkyl, or alkoxy
 947 substituents, inclusion of the nitrogen in a cyclic structure,
 948 or any combination of the above, including, but not limited to:

- 949 a. BTCP (Benzothiophenylcyclohexylpiperidine) or BCP
- 950 (Benocyclidine).

- 951 b. PCE (N-Ethyl-1-phenylcyclohexylamine) (Ethylamine analog
- 952 of phencyclidine).
- 953 c. PCPY (N-(1-Phenylcyclohexyl)-pyrrolidine) (Pyrrolidine
- 954 analog of phencyclidine).
- 955 d. PCPr (Phenylcyclohexylpropylamine).
- 956 e. TCP (1-[1-(2-Thienyl)-cyclohexyl]-piperidine) (Thiophene
- 957 analog of phencyclidine).
- 958 f. PCEEA (Phenylcyclohexyl(ethoxyethylamine)).
- 959 g. PCMPA (Phenylcyclohexyl(methoxypropylamine)).
- 960 h. Methoxetamine.
- 961 i. 3-Methoxy-PCE ((3-Methoxyphenyl)cyclohexylethylamine).
- 962 j. Bromo-PCP ((Bromophenyl)cyclohexylpiperidine).
- 963 k. Chloro-PCP ((Chlorophenyl)cyclohexylpiperidine).
- 964 l. Fluoro-PCP ((Fluorophenyl)cyclohexylpiperidine).
- 965 m. Hydroxy-PCP ((Hydroxyphenyl)cyclohexylpiperidine).
- 966 n. Methoxy-PCP ((Methoxyphenyl)cyclohexylpiperidine).
- 967 o. Methyl-PCP ((Methylphenyl)cyclohexylpiperidine).
- 968 p. Nitro-PCP ((Nitrophenyl)cyclohexylpiperidine).
- 969 q. Oxo-PCP ((Oxophenyl)cyclohexylpiperidine).
- 970 r. Amino-PCP ((Aminophenyl)cyclohexylpiperidine).
- 971 196. W-15, 4-chloro-N-[1-(2-phenylethyl)-2-
- 972 piperidinylidene]-benzenesulfonamide.
- 973 197. W-18, 4-chloro-N-[1-[2-(4-nitrophenyl)ethyl]-2-
- 974 piperidinylidene]-benzenesulfonamide.
- 975 198. AH-7921, 3,4-dichloro-N-[[1-

HB 743

2024

976 (dimethylamino)cyclohexyl)methyl]-benzamide.

977 199. U47700, trans-3,4-dichloro-N-[2-

978 (dimethylamino)cyclohexyl]-N-methyl-benzamide.

979 200. MT-45, 1-cyclohexyl-4-(1,2-diphenylethyl)-piperazine,

980 dihydrochloride.

981 Section 2. This act shall take effect July 1, 2024.